Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CinnaGen evolocumab versus Repatha in hyperlipidemia on high-intensity statin
IRCT20150303021315N32Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of evolocumab in hyperlipidemia (2 arms), sponsored by CinnaGen. Primary endpoint: Percent change of LDL-C from baseline to week 12. Started Jul 2024; status: completed.
02
Drugs
evolocumab
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on IRCT20150303021315N32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N32.